SGLT2 Inhibitors – The New HF Therapies on the Block

Published: 25 August 2020

  • Views:

    Views Icon 341
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 5
    Panel discussion
    Subodh Verma, Nikolaus Marx, Shelley Zieroth
    Up Next
Average (ratings)
No ratings
Your rating

Overview

In this Educational Symposium from the e-SPACE Heart Failure Global Web-Conference, Subodh Verma, Nikolaus Marx and Shelley Zieroth discuss SGLT2 inhibitors covering their history, a clinical perspective into what we have learned about them and how future trials might affect clinical practice. 

These videos were funded by an unrestricted educational grant from Boehringer Ingelheim & Eli Lilly and Company.

Learning objectives

  • Raise Awareness of SGLT2 Inhibitors as Cardiovascular Therapies With Cardio–Renal Benefits
  • Highlight Appropriate Patients for Initiation of an SGLT2 Inhibitor and Share With Cardiologists the Well-Established Safety Profile and Clinical Considerations for SGLT2 Inhibitor Treatment
  • Inform Cardiologists of the Current Evidence and Ongoing Trials for SGLT2 Inhibitors in Patients With HF

Agenda

  • 5 mins - Welcome & introduction - Subodh Verma
  • 15 mins - A brief history of SGLT2 inhibitors - Subodh Verma
  • 15 mins - What have we learned about SGLT2 inhibitors? A clinical perspective - Nikolaus Marx
  • 15 mins - How might future trials affect how I might treat my patients? - Shelley Zieroth
  • 10 mins - Faculty discussion (pre-recorded) - All Faculty
  • Close - Subodh Verma
  • Live Q&A and discussion - All Faculty

More from this programme

Part 1

Welcome & Introductions

Part 2

A Brief History of SGLT2 Inhibitors

Part 3

What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective

Part 4

How Might Future Trials Affect How I Treat My Patients?

Part 5

Panel discussion

Faculty Biographies

Subodh Verma

Subodh Verma

Dr Subodh Verma is a cardiac surgeon-scientist at St Michael’s Hospital and Professor in the Departments of Surgery, and Pharmacology and Toxicity at the University of Toronto. He is also the current Canada Research Chair in Cardiovascular Surgery.

Dr Verma oversees a prolific basic, translational and clinical research program. He spearheads the CARDIOLINK clinical trials platform at St Michael’s Hospital and has leadership roles in seven ongoing global heart failure trials.

View full profile
Nikolaus Marx

Nikolaus Marx

Professor of Medicine

Prof Nikolaus Marx is a Professor of Medicine / Cardiology at RWTH University Hospital Aachen, Aachen, DE.

Prof Marx's interests include cardiovascular disease in patients with comorbidities including diabetes and chronic kidney disease.

View full profile
Shelley Zieroth

Shelley Zieroth

Director, Heart Failure and Heart Transplant Clinics

Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.

She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.

Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.

View full profile